The 9th RNA-Targeted Drug Discovery & Development Summit returns to Boston, MA, on November 10–12, 2026, as the industry’s only dedicated meeting focused exclusively on RNA-targeted small molecules, bringing together leading minds from biotech, pharma and academia to advance the next generation of RNA-focused therapeutics.

As momentum continues to build across the field, driven by recent clinical progress and increasing investment in RNA-targeted approaches, the summit will explore the latest advances in direct RNA binding, splice modulation, RNA degradation, covalent translation inhibition, epitranscriptomic regulation and condensate biology. Attendees will gain valuable insights into how researchers are overcoming historic challenges in RNA druggability to develop new treatments for oncology, rare genetic diseases and neurodegenerative disorders.

A refreshed 2026 agenda will feature expert-led presentations, case studies, panel discussions and interactive workshops covering functional RNA target selection, structure-guided design, productive chemical space and emerging RNA-targeting technologies. Delegates will also discover practical strategies for improving screening approaches, measuring selectivity, validating targets and accelerating translation from discovery into clinical development.

The summit is expected to welcome 80+ RNA-targeted drug discovery experts and 22+ world-class speakers, including representatives from PTC Therapeutics, AstraZeneca, Sanofi, ReviR Therapeutics, Remix Therapeutics, Arrakis Therapeutics, Dewpoint Therapeutics and Syrna Therapeutics. Through dedicated networking opportunities and collaborative discussions, attendees will connect with the scientists, innovators and decision-makers shaping the future of RNA-targeted medicines.

Whether you are focused on RNA biology, medicinal chemistry, drug discovery, translational research or therapeutic development, this summit offers an unparalleled opportunity to access cutting-edge data, exchange ideas with pioneers in the field and help drive the next wave of innovation in RNA-targeted small molecule therapeutics. As the field continues to mature, the 9th RNA-Targeted Drug Discovery & Development Summit remains the must-attend forum for staying at the forefront of RNA drug discovery.